Medical experts in Sheffield have hailed as a "game changer" trials of a drug that could reduce the recurrence of bladder ...

Overall survival at two years was 82.2% in the durvalumab group and 75.2% in the comparator group. Durvalumab (brand name ...

The study found that patients with muscle-invasive bladder cancer had significantly less risk of cancer progressing or ...

A major clinical trial, led by the University of Sheffield, has revealed survival rates for patients with operable bladder ...

Symptoms to look out for and when to see a doctor - There are roughly 10,000 people a year diagnosed with bladder cancer in ...

Immunotherapy is a modern approach to cancer treatment that uses a patient's own immune system to help fight tumors. It has ...

Immunotherapy is a modern approach to cancer treatment that uses a patient's own immune system to help fight tumors.

Matthew R. Zibelman, MD, discusses treatment options in muscle-invasive, perioperative, and metastatic bladder cancer.

Pfizer’s “golden egg” has hatched. The subcutaneous PD-1 inhibitor improved outcomes when added to the standard of care in ...

If approved, Pfizer’s sasanlimab will distinguish itself from Merck’s blockbuster Keytruda as the first PD-1 inhibitor ...

Outcome of BCG immunotherapy of bladder cancer may ultimately depend on imbalance of Th1/Th17–Th2–regulatory T-cell axis. It is important to determine the expression and potential role of ...

A panelist discusses how Non-muscle Invasive Bladder Cancer (NMIBC) treatment varies by risk stratification (low, intermediate, and high-risk), with BCG immunotherapy being standard for high-risk ...